Industries > Pharma > Rheumatoid Arthritis (RA) Drugs Market 2017-2027

Rheumatoid Arthritis (RA) Drugs Market 2017-2027

Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets; and Investigation of Late-Stage R&D Including IL-6, JAK, BTK and GM-CSF Inhibitors

PUBLISHED: 03 November 2017
PAGES: 183
PRODUCT CODE: PHA0256

Clear
WOOCS 2.2.1
SKU: PHA0256 Categories: , , Tag:

• Do you need definitive Rheumatoid Arthritis market data?
• Succinct Rheumatoid Arthritis market analysis?
• Technological insight?
• Clear competitor analysis?
• Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.

The introduction of new biologic drugs in Rheumatoid Arthritis, has led Visiongain to publish this timely report. The Rheumatoid Arthritis Drugs market is expected to flourish in the next few years because of rise to prominence of biosimilars that provides a way of reducing the cost of treatment for patients. In addition, the arrival of new JAK inhibitors and BTK inhibitors could provide patients with oral treatments rather than taking their medications intravenously. The expected increases in efficacy are expected to feed through in the latter part of the decade driving growth to new heights. If you want to be part of this growing industry, then read on to discover how you can maximise your investment potential.

Report highlights

• 135 quantitative tables, charts, and graphs across 183 pages

• Analysis of key players in Rheumatoid Arthritis Market
• AbbVie Pharmaceuticals
• Roche Pharmaceuticals
• Johnson & Johnson
• Amgen
• Pfizer
• Merck and Co.
• BMS
• UCB

• Global Rheumatoid Arthritis market outlook and analysis from 2017-2027

• Global Rheumatoid Arthritis Drugs forecasts and analysis from 2017-2027
• Major Biologics drugs forecast 2017-2027
• Major non-biologics drugs forecast 2017-2027
• Leading drugs forecast 2017-2027

Rheumatoid Arthritis (RA) Drugs Market 2017-2027

• Regional Rheumatoid Arthritis market forecasts from 2017-2027
• US forecast 2017-2027,
• Japan forecast 2017-2027
• India forecast 2017-2027
• Germany forecast 2017-2027
• UK forecast 2017-2027
• France forecast 2017-2027
• Italy forecast 2017-2027
• Spain forecast 2017-2027
• Brazil forecast 2017-2027
• Russia forecast 2017-2027
• China forecast 2017-2027

Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to RA?
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?

Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Banks

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Rheumatoid Arthritis (RA) Drugs Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Rheumatoid Arthritis (RA) Drugs Market 2017-2027


Latest Pharma news

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

READ

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Categories